sujets spéciaux
Millepertuis
Références
1.Maury W, Price JP, Brindley MA, et al: Identification of light-independent inhibition of human immunodeficiency virus-1 infection through bioguided fractionation ofHypericum perforatum.Virol J6:101-113, 2009. doi:10.1186/1743-422X-6-101 2.Kakuda TN, Schöller-Gyüre M, Hoetelmans RM: Pharmacokinetic interactions betweenetravirineand non-antiretroviral drugs.Clin Pharmacokinet50(1):25-39, 2011. doi: 10.2165/11534740-000000000-00000 3.Solomon D, Adams J, Graves N: Economic evaluation of St. John's wort (Hypericum perforatum) for the treatment of mild to moderate depression.J Affect Disord148(2-3):228-234, 2013. doi: 10.1016/j.jad.2012.11.064 4.van Gurp G, Meterissian GB, Haiek LN, et al: St John's wort orsertraline? Randomized controlled trial in primary care.Can Fam Physician48:905-912, 2002 5.Woelk H: Comparison of St John's wort andimipraminefor treating depression: randomised controlled trial.BMJ321(7260):536-539, 2000. doi: 10.1136/bmj.321.7260.536 6.Fava M, Alpert J, Nierenberg AA, et al: A double-blind, randomized trial of St John's wort,fluoxetine, and placebo in major depressive disorder.J Clin Psychopharmacol25(5):441-447, 2005. doi:10.1097/01.jcp.0000178416.60426.29 7.Sarris J, Fava M, Schweitzer I, et al: St John's wort (Hypericum perforatum) versussertralineand placebo in major depressive disorder: continuation data from a 26-week RCT.Pharmacopsychiatry45(7):275-278, 2012. doi: 10.1055/s-0032-1306348 8.Seifritz E, Hatzinger M, Holsboer-Trachsler E: Efficacy of Hypericum extract WS(R) 5570 compared withparoxetinein patients with a moderate major depressive episode - a subgroup analysis.Int J Psychiatry Clin Pract20(3):126-32, 2016. doi: 10.1080/13651501.2016.1179765 9.Apaydin EA, Maher AR, Shanman R, et al: A systematic review of St. John's wort for major depressive disorder.Systematic Reviews5:148, 2016. doi: 10.1186/s13643-016-0325-2 10.Ng QX, Venkatanarayanan N, Ho CY: Clinical use of Hypericum perforatum (St John's wort) in depression: a meta-analysis.J Affect Disord210:211-221, 2017. doi: 10.1016/j.jad.2016.12.048 11.Najafizadeh P, Hashemian F, Mansouri P, et al: The evaluation of the clinical effect of topical St Johns wort (Hypericum perforatum L.) in plaque type psoriasis vulgaris: a pilot study.Australas J53(2):131-135, 2012. doi: 10.1111/j.1440-0960.2012.00877.x 12.Rook AH, Wood GS, Duvic M, et al: A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis.J Am Acad Dermatol63(6):984-990, 2010. doi: 10.1016/j.jaad.2010.02.039 13.Weber W, Vander Stoep A, McCarty RL, et al:Hypericum perforatum(St John's wort) for attention-deficit/hyperactivity disorder in children and adolescents: a randomized controlled trial.JAMA299(22):633-2641, 2008. doi: 10.1001/jama.299.22.2633 14.Fisher KA, Patel P, Abualula S, Concepion L: St. John's wort-induced supraventricular tachycardia.Cureus13(4):e14356, 2021. doi:10.7759/cureus.14356 15.Borrelli F, Izzo AA: Herb-drug interactions with St John's wort (Hypericum perforatum): an update on clinical observations.AAPS J11(4):710-727, 2009. doi: 10.1208/s12248-009-9146-8 16.Nadkarni A, Oldham MA, Howard M, et al: Drug-drug interactions betweenwarfarinand psychotropics: updated review of the literature.Pharmacotherapy32(10):932-942. 2012. doi: 10.1002/j.1875-9114.2012.01119 17.Tsai HH, Lin HW, Simon Pickard A, et al: Evaluation of documented drug interactions and contraindications associated with herbs and dietary supplements: a systematic literature review.Int J Clin Pract66(11):1056-1078, 2012. doi: 10.1111/j.1742-1241.2012.03008.x 